
|Articles|September 10, 2014
PRA Health Sciences Files for Initial Public Offering
PRA Health Sciences announced that it has filed a registration statement with the US Securities and Exchange Commission
Advertisement
PRA Health Sciences announced that it has filed a registration statement with the U.S. Securities and Exchange Commission relating to a proposed initial public offering (“IPO”) of shares of its common stock by PRA Health Sciences. The number of shares to be offered and the price range has not yet been determined.
Read the full release
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Why Clinical Trial Modernization Fails Without Point-of-Care Data: Q&A with Richard Graham, PhD, TruTechnologies
2
FDA Makes Case for Overhauling Early Clinical Development to Reclaim US Leadership
3
ACT Brief: Lean Development Through Fractional Teams and Partners, FDA Expedited IND Pilot for Phase I Acceleration, and Tudriqev Accelerated Approval for Anti-PD-1-Refractory Melanoma
4
ACT Brief: Commercial Strategy Shaping Early Clinical Development, Real-Time Trials Require Operational Infrastructure, and AI Site Engagement Gap
5



